Swiss - Delayed Quote CHF

Roche Holding AG (RO.SW)

277.40

0.00

(0.00%)

At close: May 12 at 5:30:25 PM GMT+2

Roche plans $700m manufacturing plant in the US

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

Pharmaceutical Technology 7 hours ago

ROG.SW
Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.

MedTech Dive 9 hours ago

ROG.SW
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.

PR Newswire 10 hours ago

RHHBF

RHHBY

RHHVF
Roche boosts US presence with new $700 million North Carolina facility

The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines. Separately, Roche also announced plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030, to manufacture continuous glucose monitoring systems.

Reuters 11 hours ago

ROG.SW
Roche and Genentech Announce New North Carolina Manufacturing Facility

SOUTH SAN FRANCISCO, Calif., May 12, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC.

Business Wire 12 hours ago

RHHBF

RHHBY

RHHVF
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

The Wall Street Journal 15 hours ago

069620.KS

CHGCF

CHGCY
Trump is hailing $2 trillion in new company investments. Most of it comes from Big Tech.

President Trump has touted $2 trillion in new company investments since Inauguration Day. The lion's share comes from Big Tech, according to a Yahoo Finance analysis.

Yahoo Finance 2 days ago

ORCL

RHHBF

RHHBY
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.

Zacks 3 days ago

PRTA

ROG.SW
Zealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...

Zealand Pharma AS (ZLDPF) reports robust financials and transformative partnerships, setting the stage for future growth in the obesity and rare disease markets.

GuruFocus.com 3 days ago

ZEAL.CO

ROG.SW
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.

Zacks 5 days ago

SRPT

ARWR

ROG.SW
Roche introduces diagnostic test for liver fibrosis severity assessment

The test operates on Roche's cobas analysers and requires one assay, delivering outcomes in 18 minutes.

Medical Device Network 5 days ago

ROG.SW
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide1The test delivers results in just 18 minutes on Roche’s cobas analysers, providing a fast and reliable diagnostic method.The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies. Basel, 0

GlobeNewswire 6 days ago

RHHBF

RHHBY

RHHVF
Entering the era of prenatal gene therapies

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are hurdles to overcome.

Pharmaceutical Technology 10 days ago

ROG.SW
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.

Yahoo Finance 11 days ago

PFE

JNJ

RHHBF
Roche Holding AG (RHHBY) is a Great Momentum Stock: Should You Buy?

Does Roche Holding AG (RHHBY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 11 days ago

ROG.SW
How Roche revitalized customer analytics across its data estate

As the nearly 130-year-old pharmaceutical company consolidated its CRM systems, it cut down on vendor costs and paved the way for AI adoption.

CIO Dive 12 days ago

ROG.SW
Is Roche Holding (RHHBY) Stock Outpacing Its Medical Peers This Year?

Here is how Roche Holding AG (RHHBY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks 12 days ago

ROG.SW
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home1-4 Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings3Phesgo has the potential to reduce treatment administration costs by up to 80% in Western Europe, and 85% of patients prefer SC over IV administ

GlobeNewswire 12 days ago

RHHBF

RHHBY

RHHVF
FDA grants breakthrough status to Roche’s VENTANA TROP2 device

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment.

Medical Device Network 13 days ago

ROG.SW
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology. Basel, 29 Apri

GlobeNewswire 13 days ago

RHHBF

RHHBY

RHHVF

Performance Overview

Return	RO.SW	MSCI WORLD (^990100-USD-STRD)
YTD	+5.71%	+2.11%
1-Year	+15.90%	+11.04%
3-Year	-14.73%	+43.16%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (RO.SW)

Roche plans $700m manufacturing plant in the US

Roche plans $550M expansion of Indianapolis site to manufacture CGMs

Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

Roche boosts US presence with new $700 million North Carolina facility

Roche and Genentech Announce New North Carolina Manufacturing Facility

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

Trump is hailing $2 trillion in new company investments. Most of it comes from Big Tech.

Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

Zealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Roche introduces diagnostic test for liver fibrosis severity assessment

Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

Entering the era of prenatal gene therapies

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Roche Holding AG (RHHBY) is a Great Momentum Stock: Should You Buy?

How Roche revitalized customer analytics across its data estate

Is Roche Holding (RHHBY) Stock Outpacing Its Medical Peers This Year?

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

FDA grants breakthrough status to Roche’s VENTANA TROP2 device

Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

Performance Overview